Ki-67 index Introduction (What it is)
Ki-67 index is a lab measurement that estimates how many tumor cells are actively dividing.
It is reported as a percentage based on staining of a biopsy or surgical tissue sample.
Clinicians use it most often in cancer pathology reports to describe tumor “proliferation” (growth activity).
It is commonly discussed in solid tumors and some blood cancers, alongside tumor grade and stage.
Why Ki-67 index used (Purpose / benefits)
Cancer care often depends on understanding not only where a cancer is and what type it is, but also how fast it appears to be growing. The Ki-67 index helps address that need by providing a standardized way to describe tumor cell proliferation.
In general terms, Ki-67 index is used to:
- Support diagnosis and classification when combined with tumor histology (microscope appearance) and other biomarkers.
- Add prognostic context, meaning it may help estimate how aggressive a tumor’s behavior could be in groups of patients. (How much weight it carries varies by cancer type and stage.)
- Contribute to grading systems for certain cancers where proliferation is part of formal grading or risk grouping.
- Inform treatment discussions by helping clinicians compare “lower-proliferation” versus “higher-proliferation” disease, especially when multiple reasonable options exist. The degree to which it changes management varies by clinician and case.
- Provide a baseline that can be compared with later samples in selected situations (for example, after treatment or at recurrence), recognizing that results can differ due to biology and testing factors.
Ki-67 index does not detect cancer by itself, and it does not replace imaging, staging, or full pathology interpretation. It is one piece of a larger clinical picture.
Indications (When oncology clinicians use it)
Ki-67 index is typically ordered or reported when it may add meaningful context to a pathology diagnosis, such as:
- Newly diagnosed cancers where tumor grade and proliferation influence classification or risk assessment
- Breast cancer evaluations where proliferation may be considered alongside receptor status and other markers (use and cutoffs vary by clinician and case)
- Neuroendocrine tumors, where Ki-67 can be part of grading in many settings (exact approach varies by tumor site and pathology protocol)
- Some lymphomas and other hematologic malignancies, where a proliferation index can support subtyping or risk assessment
- Tumors with borderline features where additional biologic information may help refine interpretation
- Cases where clinicians want to understand whether a tumor appears indolent (slow-growing) versus more proliferative
- Selected situations after treatment or at relapse where a new biopsy is done and biology may have changed
Contraindications / when it’s NOT ideal
Ki-67 index is not “contraindicated” in the way a drug or surgery can be, but there are situations where it may be less reliable or less useful, or where another approach may be preferred:
- Insufficient or poor-quality tissue, such as very small biopsies with few viable tumor cells
- Suboptimal fixation or processing, which can reduce staining reliability (a pre-analytic laboratory issue)
- Samples with extensive necrosis (dead tissue) or heavy crush artifact that makes counting difficult
- Tumors with high heterogeneity (different areas behaving differently), where a small sample may not represent the whole tumor
- When a cancer’s standard management does not rely on proliferation measures, making Ki-67 less likely to change decisions
- When a patient has already received treatment and the tissue shows treatment effect, which can complicate interpretation (whether Ki-67 should be repeated varies by clinician and case)
- When a different metric is more established for that tumor type, such as mitotic count, a validated tumor grade, molecular profiling, or a disease-specific scoring system
How it works (Mechanism / physiology)
Ki-67 is a protein expressed in the nucleus of cells that are actively progressing through the cell cycle (in simple terms, cells that are preparing to divide or are dividing). Cells that are resting (in a non-dividing state) generally do not show Ki-67 staining.
In clinical practice:
- A pathologist uses immunohistochemistry (IHC), a staining method that applies antibodies to tissue on a microscope slide.
- Tumor cell nuclei that contain Ki-67 become stained, allowing the pathologist to estimate the proportion of proliferating tumor cells.
- The Ki-67 index is reported as the percentage of tumor cells showing positive nuclear staining within a defined area.
This is a diagnostic pathology measurement, not a therapy. Concepts like “onset,” “duration,” or “reversibility” do not apply the way they would for a medication. The closest relevant idea is that:
- Ki-67 reflects the tumor’s proliferative activity at the time and site sampled.
- It can vary within the tumor (hot spots versus lower-activity regions) and can change over time, including after treatment or at recurrence.
- Results can also vary due to technical factors (how tissue is collected, fixed, stained, and scored).
Ki-67 index Procedure overview (How it’s applied)
Ki-67 index is not a stand-alone procedure. It is a test performed on tumor tissue that has already been collected through a biopsy or surgery. A typical high-level workflow looks like this:
-
Evaluation/exam
A clinician evaluates symptoms, physical findings, and history, and decides whether imaging and/or biopsy is needed. -
Imaging/biopsy/labs
Imaging may identify a mass or abnormal area. A biopsy or surgical specimen provides tissue for diagnosis. Routine labs may also be part of the workup depending on cancer type. -
Pathology diagnosis
A pathologist examines the tissue to determine cancer type, grade (when applicable), and key features such as invasion and margins (for surgical samples). -
Ki-67 testing (when ordered or routinely included)
The lab performs Ki-67 IHC staining. The pathologist selects areas to evaluate and estimates or counts the proportion of tumor nuclei that stain positive. -
Reporting
The Ki-67 index is reported as a percentage, sometimes with brief context (for example, “hot spot” vs “overall” approach), depending on the lab. -
Staging
Clinicians combine pathology with imaging and other studies to determine cancer stage when staging applies. -
Treatment planning
The oncology team considers Ki-67 alongside stage, grade, molecular markers, patient goals, and overall health. How much Ki-67 influences decisions varies by cancer type and stage. -
Intervention/therapy
Treatment may include surgery, radiation, systemic therapy, or combinations, based on the full clinical picture. -
Response assessment and follow-up/survivorship
Response is assessed through symptoms, exams, imaging, and sometimes lab tests. Ki-67 is not routinely tracked over time unless a new tissue sample is obtained for a clinical reason.
Types / variations
Ki-67 index can vary in how it is measured, reported, and used, depending on the disease context and laboratory standards. Common variations include:
-
Manual visual estimation vs counted scoring
Some reports use a visual estimate, while others use more formal counting methods. The method can affect reproducibility. -
Hot spot scoring vs averaged fields
A “hot spot” approach focuses on the most proliferative area, while averaging looks across multiple regions. Which is preferred varies by tumor type and lab protocol. -
Different antibodies and staining platforms
Labs may use different validated reagents and instruments. These technical differences can contribute to variability. -
Digital image analysis vs pathologist-only scoring
Some centers use software-assisted scoring to improve consistency, though implementation and validation vary. -
Reported as a single percentage vs ranges or categories
Some reports provide a specific percentage; others group results into categories. Cutoffs, when used, vary by clinician and case. -
Tumor-specific integration
In some cancers, Ki-67 is one optional data point; in others, it may be more central to grading or classification. This is highly tumor-dependent. -
Solid-tumor vs hematologic context
In solid tumors, Ki-67 is often discussed with grade and biomarkers. In hematologic malignancies, it may be framed as a proliferation or labeling index supporting subtyping.
Pros and cons
Pros:
- Helps describe tumor proliferation in a way that is more objective than words alone
- Can add prognostic context when interpreted within a specific cancer type
- May support tumor classification or grading in selected diseases
- Uses tissue that is often already collected for diagnosis (no separate procedure in many cases)
- Can be integrated with other biomarkers to create a more complete biologic profile
- May help explain why tumors with similar stage can behave differently (varies by cancer type and stage)
Cons:
- Variability in scoring between observers and between laboratories can affect consistency
- Results can be influenced by pre-analytic factors (fixation time, tissue handling) and analytic factors (staining method)
- Tumor heterogeneity means a small biopsy may not represent the entire tumor’s proliferation
- Cutoffs are not universal; what counts as “high” or “low” varies by cancer type and clinical context
- It is not diagnostic by itself and should not be interpreted without the full pathology and clinical picture
- A single Ki-67 index does not capture other key tumor behaviors (spread potential, immune environment, molecular drivers)
Aftercare & longevity
Because Ki-67 index is a measurement, there is no direct “aftercare” for the index itself. Aftercare relates to the biopsy or surgery used to obtain tissue and to the broader cancer care plan.
In terms of how Ki-67 fits into longer-term care:
- The impact of Ki-67 on outcomes and planning varies by cancer type and stage and by how strongly that disease’s evidence base links proliferation to prognosis or treatment response.
- Ki-67 is usually interpreted alongside stage, grade, margins (if surgery), lymph node status, and biomarkers (such as hormone receptors or other tumor-specific markers).
- Long-term outcomes are influenced by multiple factors, including tumor biology, treatment intensity, treatment tolerance, comorbidities, and access to follow-up care.
- If a tumor recurs or progresses and a new biopsy is performed, Ki-67 may be reassessed, recognizing that changes can reflect true biologic evolution and/or differences in sampling and testing.
- Survivorship planning typically focuses on monitoring for recurrence, managing late effects, rehabilitation needs, psychosocial support, and health maintenance. Ki-67 is rarely the sole driver of survivorship follow-up schedules.
Alternatives / comparisons
Ki-67 index is one way to assess proliferation, but it is not the only method, and it is not always the most clinically decisive measure. Common alternatives or complementary approaches include:
-
Mitotic count and tumor grade
Many pathology systems use the number of dividing cells seen under the microscope (mitoses) and other structural features to assign grade. In some cancers, grade is more standardized than Ki-67. -
Other proliferation-associated markers
Depending on the disease and institution, other markers may be used in select settings (for example, markers that highlight mitotic figures). Availability and validation vary. -
Molecular profiling and gene expression assays
Some cancers use molecular tests to estimate recurrence risk or likely benefit from systemic therapies. These tests assess gene activity rather than staining a single protein. Use depends on cancer type and clinical scenario. -
Imaging and clinical tempo
In certain cancers, imaging findings over time (growth rate) and symptom progression can provide practical information about tumor behavior, especially when repeat biopsy is not feasible. -
Observation/active surveillance vs immediate treatment
For some slow-growing cancers, careful monitoring may be an option. Ki-67 can sometimes support a discussion about tumor aggressiveness, but it rarely replaces staging, imaging, and established risk models. -
Standard treatments vs clinical trials
When standard options are limited or multiple reasonable strategies exist, clinical trials may be considered. Ki-67 may be used as an eligibility or stratification factor in some studies, depending on trial design.
Overall, Ki-67 index is best viewed as complementary—a helpful data point that should be weighed against more established disease-specific predictors.
Ki-67 index Common questions (FAQ)
Q: Does the Ki-67 index diagnose cancer?
No. Ki-67 index does not diagnose cancer on its own. It is interpreted after a diagnosis is made from tissue, and it helps describe how actively the tumor cells are proliferating.
Q: What does a “high” Ki-67 index mean?
In general, a higher Ki-67 index suggests a larger fraction of tumor cells are actively dividing. The clinical meaning of “high” depends on the specific cancer type, the test method, and how the result fits with stage, grade, and other biomarkers.
Q: Can the Ki-67 index be low even if cancer is serious?
Yes. Some cancers can spread or cause significant health problems even when they have a lower proliferation index. Cancer behavior depends on many factors beyond proliferation alone.
Q: Is Ki-67 index testing painful or does it require anesthesia?
The Ki-67 index is measured on tissue, so any discomfort relates to the biopsy or surgery used to obtain the sample. Whether anesthesia is used depends on the biopsy type and body site, and clinicians choose approaches based on safety and patient comfort.
Q: Are there side effects from Ki-67 testing?
The lab test itself has no physical side effects because it is performed on tissue outside the body. Risks, if any, come from the procedure that collected the tissue (such as biopsy), which varies by location and method.
Q: How long does it take to get Ki-67 results?
Turnaround time varies by laboratory workflow and whether additional stains are needed. Ki-67 is often reported with other pathology results or as an add-on test after the initial diagnosis is established.
Q: Will the Ki-67 index change my treatment plan?
Sometimes it can influence discussions, especially in cancers where proliferation is part of risk assessment or grading. In other cases, it may be recorded for context but not change decisions. This varies by clinician and case.
Q: Can Ki-67 index results differ between labs or between two samples?
Yes. Differences can occur due to tumor heterogeneity (different areas of the tumor behaving differently), timing (before or after treatment), and variations in staining or scoring methods. Clinicians interpret the result in context and may consider repeat testing if a new biopsy is clinically indicated.
Q: What is the cost of Ki-67 index testing?
Costs vary widely based on country, insurance coverage, hospital billing, and whether the test is bundled into pathology charges. Patients often receive the most accurate estimate by asking the treating facility’s billing team about pathology and immunohistochemistry charges.
Q: Does Ki-67 index testing affect work, activity, or fertility?
Ki-67 testing itself does not affect work, activity, or fertility because it is performed on tissue. Any temporary activity limits come from the biopsy or surgery, and fertility concerns usually relate to cancer treatments (such as chemotherapy, hormonal therapy, or radiation), not the Ki-67 measurement.